Illumina and Pacific Biosciences terminate $1.2bn deal
03-01-2020
Taiwanese firm accuses Pacific Biosciences of infringing sequencing tech
30-09-2019
Natee Meepian / iStockphoto.com
Gene-sequencing company Illumina has agreed to buy competitor Pacific Biosciences (PacBio) for $1.2 billion.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Illumina, Pacific Biosciences, mergers and acquisitions, M&A, DNA sequencing, genomics, genetics
